The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
The need for hot-melt extrusion (HME) polymers is expected to grow as the pharma industry moves to implement more continuous and sustainable processes.
Study achieves primary endpoint of radiographic progression-free survival
This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.
The ninth acquisition since 2018
3D CMOS chip for connecting electroactive tissues and organoids to software
Subscribe To Our Newsletter & Stay Updated
